Click on image to view larger version.
FIGURE 3. Comparison of dopamine synthesis and vesicular storage (18F-labeled 6-fluoro-L-DOPA [18F-FDOPA] PET, top row) and D2 receptor binding (11C-raclopride [RACLO] PET, middle row) in Parkinson's disease (PD) and multiple system atrophy with parkinsonian symptoms (MSA-P). FDOPA uptake is reduced in putamen in all conditions (red stars), whereas D2 receptor binding is increased at an early stage of PET (HY stage I, yellow plus sign, second column), back to normal in advanced PD (HY stage IV, third column), and reduced in MSA-P (red plus sign, fourth column).
